Claims for Patent: 9,085,620

Summary for Patent: 9,085,620

Title:	Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Abstract:	The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s):	Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL), Banerjee; Subhashis (Princeton, NJ), Taylor; Lori K. (Boston, MA), Spiegler; Clive E. (Skillman, NJ), Tracey; Daniel E. (Harvard, MA), Chartash; Elliot K. (Marietta, GA), Barchuk; William T. (San Diego, CA), Yan; Philip (Vernon Hills, IL), Murtaza; Anwar (Westborough, MA), Salfeld; Jochen G. (North Grafton, MA), Fischkoff; Steven A. (Short Hills, NJ), Granneman; George R. (Marco Island, FL)
Assignee:	AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:	14/681,713
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,085,620
Patent Claims:	1. A method of administering adalimumab for treatment of psoriatic arthritis, comprising filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab to a patient having psoriatic arthritis every other week. 2. The method of claim 1, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 3. The method of claim 2, wherein said vessels each contains 40 mg of adalimumab. 4. The method of claim 1, wherein said vessel are syringes. 5. The method of claim 4, wherein adalimumab in said syringes is formulated at a concentration of 50 mg/ml. 6. The method of claim 5, wherein said syringes each contains 40 mg of adalimumab. 7. The method of claim 1, wherein said patient has erosive polyarthritis associated with psoriatic arthritis. 8. The method of claim 7, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 9. The method of claim 8, wherein said vessels are syringes and each contains 40 mg of adalimumab. 10. The method of claim 1, wherein said treatment inhibits progression of structural damage in said patient. 11. The method of claim 10, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 12. The method of claim 11, wherein said vessels are syringes and each contains 40 mg of adalimumab. 13. A method of preparing adalimumab for treating psoriatic arthritis, comprising filling adalimumab into vessels and providing said adalimumab for treatment, wherein said treatment comprises subcutaneously administering 40 mg of said adalimumab to a patient having psoriatic arthritis every other week. 14. The method of claim 13, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 15. The method of claim 14, wherein said vessels each contains 40 mg of adalimumab. 16. The method of claim 13, wherein said vessels are syringes. 17. The method of claim 16, wherein adalimumab in said syringes is formulated at a concentration of 50 mg/ml. 18. The method of claim 17, wherein said syringes each contains 40 mg of adalimumab. 19. The method of claim 13, wherein said patient has at least 3 swollen joints, at least 3 tender joints, and erosive polyarthritis associated with psoriatic arthritis. 20. The method of claim 19, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 21. The method of claim 20, wherein said vessels are syringes and each contains 40 mg of adalimumab. 22. The method of claim 13, wherein said treatment inhibits progression of structural damage in said patient. 23. The method of claim 22, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml. 24. The method of claim 23, wherein said vessels are syringes and each contains 40 mg of adalimumab. 25. The method of claim 13, wherein said treatment reduces or inhibits psoriatic arthritis symptoms in said patient. 26. The method of claim 25, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml, and said vessels are syringes and each contains 40 mg adalimumab. 27. The method of claim 13, wherein said patient achieves at least a 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment. 28. The method of claim 27, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml, and said vessels are syringes and each contains 40 mg of adalimumab. 29. The method of claim 13, wherein said patient achieves at least a 90% reduction in Psoriasis Area and Severity Index (PASI) score at week 24 of the treatment. 30. The method of claim 29, wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml, and said vessels are syringes and each contains 40 mg of adalimumab.

Details for Patent 9,085,620

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2025-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2025-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2025-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2025-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2025-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2025-05-16